Compare · CGC vs CYAN
CGC vs CYAN
Side-by-side comparison of Canopy Growth Corporation (CGC) and Cyanotech Corporation (CYAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and CYAN operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 164.4x CYAN ($17.4M).
- CGC has hit the wire 12 times in the past 4 weeks while CYAN has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 0 for CYAN).
- Company
- Canopy Growth Corporation
- Cyanotech Corporation
- Price
- -
- -
- Market cap
- $2.86B
- $17.4M
- 1M return
- +14.53%
- -
- 1Y return
- -27.55%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 19
- 0
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Cyanotech Corporation
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Latest CGC
- Officer Gedeon Christelle sold $19,616 worth of shares (13,344 units at $1.47), decreasing direct ownership by 2% to 692,162 units (SEC Form 4) to cover taxes
- Officer Stewart Thomas Carlton sold $3,280 worth of shares (2,231 units at $1.47), decreasing direct ownership by 0.36% to 614,167 units (SEC Form 4) to satisfy withholding obligation
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form DEF 14A filed by Canopy Growth Corporation
- Canopy Growth Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest CYAN
- SEC Form 15-12G filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- SEC Form SC 13E3 filed by Cyanotech Corporation
- SEC Form 10-Q filed by Cyanotech Corporation
- Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
- SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.
- SEC Form 3 filed by new insider Miyashiro Jennifer A.S.
- Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)
- Director Vied David L was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 29% to 225,138 units (SEC Form 4)